{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,12]],"date-time":"2025-07-12T01:02:33Z","timestamp":1752282153774,"version":"3.37.3"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T00:00:00Z","timestamp":1679961600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T00:00:00Z","timestamp":1679961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Science and Technology Key Program of Hunan Province Grants","award":["2016SK2066"],"award-info":[{"award-number":["2016SK2066"]}]},{"name":"Hunan Province Chinese Medicine Research Program Grants","award":["201940"],"award-info":[{"award-number":["201940"]}]},{"name":"Science and Technology Key Program of Hunan Provincial Health Committee","award":["20201904"],"award-info":[{"award-number":["20201904"]}]},{"DOI":"10.13039\/501100004761","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"crossref","award":["2021JJ30753"],"award-info":[{"award-number":["2021JJ30753"]}],"id":[{"id":"10.13039\/501100004761","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Changsha Central Hospital Affiliated to University of South China Foundation of key Program","award":["YNKY202205"],"award-info":[{"award-number":["YNKY202205"]}]},{"name":"Hunan Province Foundation of High-level Health Talent","award":["225 Program"],"award-info":[{"award-number":["225 Program"]}]},{"name":"Key Scientific Research Projects of Hunan Provincial Department of Education","award":["22A0320"],"award-info":[{"award-number":["22A0320"]}]},{"name":"Changsha Municipal Natural Science Foundation","award":["kp2014020"],"award-info":[{"award-number":["kp2014020"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1007\/s00228-023-03484-6","type":"journal-article","created":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T06:02:35Z","timestamp":1679983355000},"page":"663-670","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Association between the NEP rs701109 polymorphism and the clinical efficacy and safety of sacubitril\/valsartan in Chinese patients with heart failure"],"prefix":"10.1007","volume":"79","author":[{"given":"Hong-Yu","family":"Luo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Chen","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui-Zhi","family":"Long","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zi-Wei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuo-Guo","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng-Jiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong-Li","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cai-Xia","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xing-Yu","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ran","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,3,28]]},"reference":[{"issue":"9","key":"3484_CR1","doi-asserted-by":"publisher","first-page":"e139","DOI":"10.1161\/CIR.0000000000000757","volume":"141","author":"SS Virani","year":"2020","unstructured":"Virani SS, Alonso A, Benjamin EJ et al (2020) Heart Disease and Stroke Statistics-2020 Update: A Report From the American Heart Association. Circulation 141(9):e139\u2013e596","journal-title":"Circulation"},{"issue":"5","key":"3484_CR2","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.jchf.2017.12.006","volume":"6","author":"KE Van Nuys","year":"2018","unstructured":"Van Nuys KE, Xie Z, Tysinger B et al (2018) Innovation in Heart Failure Treatment: Life Expectancy, Disability, and Health Disparities. JACC Heart Fail 6(5):401\u2013409","journal-title":"JACC Heart Fail"},{"issue":"10","key":"3484_CR3","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/nrcardio.2017.65","volume":"14","author":"SM Dunlay","year":"2017","unstructured":"Dunlay SM, Roger VL, Redfield MM (2017) Epidemiology of heart failure with preserved ejection fraction. Nat Rev Cardiol 14(10):591\u2013602","journal-title":"Nat Rev Cardiol"},{"issue":"4","key":"3484_CR4","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1093\/ndt\/gfz058","volume":"35","author":"R Haynes","year":"2020","unstructured":"Haynes R, Zhu D, Judge PK et al (2020) Chronic kidney disease, heart failure and neprilysin inhibition. Nephrol Dial Transplant 35(4):558\u2013564","journal-title":"Nephrol Dial Transplant"},{"issue":"15","key":"3484_CR5","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1093\/eurheartj\/ehw570","volume":"38","author":"M Bohm","year":"2017","unstructured":"Bohm M, Young R, Jhund PS et al (2017) Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril\/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF. Eur Heart J 38(15):1132\u20131143","journal-title":"Eur Heart J"},{"issue":"1","key":"3484_CR6","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1161\/HYPERTENSIONAHA.119.14057","volume":"75","author":"SE Kjeldsen","year":"2020","unstructured":"Kjeldsen SE, von Lueder TG, Smiseth OA et al (2020) Medical Therapies for Heart Failure With Preserved Ejection Fraction. Hypertension 75(1):23\u201332","journal-title":"Hypertension"},{"issue":"5","key":"3484_CR7","doi-asserted-by":"publisher","first-page":"e00844","DOI":"10.1002\/prp2.844","volume":"9","author":"E Charuel","year":"2021","unstructured":"Charuel E, Menini T, Bedhomme S et al (2021) Benefits and adverse effects of sacubitril\/valsartan in patients with chronic heart failure: A systematic review and meta-analysis. Pharmacol Res Perspect 9(5):e00844","journal-title":"Pharmacol Res Perspect"},{"issue":"16","key":"3484_CR8","doi-asserted-by":"publisher","first-page":"e021459","DOI":"10.1161\/JAHA.121.021459","volume":"10","author":"SJ Greene","year":"2021","unstructured":"Greene SJ, Choi S, Lippmann SJ et al (2021) Clinical Effectiveness of Sacubitril\/Valsartan Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction. J Am Heart Assoc 10(16):e021459","journal-title":"J Am Heart Assoc"},{"issue":"9","key":"3484_CR9","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1177\/2047487320915663","volume":"28","author":"M Gatti","year":"2021","unstructured":"Gatti M, Antonazzo IC, Diemberger I et al (2021) Adverse events with sacubitril\/valsartan in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system. Eur J Prev Cardiol 28(9):983\u2013989","journal-title":"Eur J Prev Cardiol"},{"issue":"10","key":"3484_CR10","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.jchf.2020.06.008","volume":"8","author":"DD Berg","year":"2020","unstructured":"Berg DD, Braunwald E, DeVore AD et al (2020) Efficacy and Safety of Sacubitril\/Valsartan by Dose Level Achieved in the PIONEER-HF Trial. JACC Heart Fail 8(10):834\u2013843","journal-title":"JACC Heart Fail"},{"key":"3484_CR11","doi-asserted-by":"publisher","first-page":"754499","DOI":"10.3389\/fcvm.2021.754499","volume":"8","author":"D Pascual-Figal","year":"2021","unstructured":"Pascual-Figal D, Bayes-Genis A, Beltran-Troncoso P et al (2021) Sacubitril-Valsartan, Clinical Benefits and Related Mechanisms of Action in Heart Failure With Reduced Ejection Fraction. A Review. Front Cardiovasc Med 8:754499","journal-title":"Front Cardiovasc Med"},{"issue":"5","key":"3484_CR12","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1007\/s12265-013-9491-y","volume":"6","author":"DE Lanfear","year":"2013","unstructured":"Lanfear DE, Sunkara B, Li J et al (2013) Association of genetic variation with gene expression and protein abundance within the natriuretic peptide pathway. J Cardiovasc Transl Res 6(5):826\u2013833","journal-title":"J Cardiovasc Transl Res"},{"issue":"2","key":"3484_CR13","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1002\/ehf2.13220","volume":"8","author":"C Henke","year":"2021","unstructured":"Henke C, Haufe S, Ziehl D et al (2021) Low-fat hypocaloric diet reduces neprilysin in overweight and obese human subjects. ESC Heart Fail 8(2):938\u2013942","journal-title":"ESC Heart Fail"},{"issue":"6","key":"3484_CR14","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1136\/jnnp.74.6.749","volume":"74","author":"M Yamada","year":"2003","unstructured":"Yamada M, Sodeyama N, Itoh Y et al (2003) Association of neprilysin polymorphism with cerebral amyloid angiopathy. J Neurol Neurosurg Psychiatry 74(6):749\u2013751","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"12","key":"3484_CR15","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1136\/jnnp.2004.036574","volume":"75","author":"S Helisalmi","year":"2004","unstructured":"Helisalmi S, Hiltunen M, Vepsalainen S et al (2004) Polymorphisms in neprilysin gene affect the risk of Alzheimer\u2019s disease in Finnish patients. J Neurol Neurosurg Psychiatry 75(12):1746\u20131748","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"3484_CR16","doi-asserted-by":"publisher","first-page":"e02002","DOI":"10.1002\/brb3.2002","volume":"11","author":"S Chen","year":"2021","unstructured":"Chen S, Mima D, Jin H et al (2021) The Association between Neprilysin gene polymorphisms and Alzheimer\u2019s disease in Tibetan population. Brain Behav 11(3):e02002","journal-title":"Brain Behav"},{"issue":"5","key":"3484_CR17","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1038\/tpj.2012.25","volume":"13","author":"EM Bruxel","year":"2013","unstructured":"Bruxel EM, Salatino-Oliveira A, Genro JP et al (2013) Association of a carboxylesterase 1 polymorphism with appetite reduction in children and adolescents with attention-deficit\/hyperactivity disorder treated with methylphenidate. Pharmacogenomics J 13(5):476\u2013480","journal-title":"Pharmacogenomics J"},{"issue":"11","key":"3484_CR18","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1124\/dmd.117.077669","volume":"45","author":"X Wang","year":"2017","unstructured":"Wang X, Rida N, Shi J et al (2017) A Comprehensive Functional Assessment of Carboxylesterase 1 Nonsynonymous Polymorphisms. Drug Metab Dispos 45(11):1149\u20131155","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"3484_CR19","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1124\/dmd.108.024943","volume":"37","author":"HJ Zhu","year":"2009","unstructured":"Zhu HJ, Markowitz JS (2009) Activation of the antiviral prodrug oseltamivir is impaired by two newly identified carboxylesterase 1 variants. Drug Metab Dispos 37(2):264\u2013267","journal-title":"Drug Metab Dispos"},{"issue":"7\u20138","key":"3484_CR20","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.neuropharm.2009.08.014","volume":"57","author":"Z Nemoda","year":"2009","unstructured":"Nemoda Z, Angyal N, Tarnok Z et al (2009) Carboxylesterase 1 gene polymorphism and methylphenidate response in ADHD. Neuropharmacology 57(7\u20138):731\u2013733","journal-title":"Neuropharmacology"},{"issue":"7","key":"3484_CR21","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1111\/bcp.13237","volume":"83","author":"C Stage","year":"2017","unstructured":"Stage C, Jurgens G, Guski LS et al (2017) The impact of CES1 genotypes on the pharmacokinetics of methylphenidate in healthy Danish subjects. Br J Clin Pharmacol 83(7):1506\u20131514","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"3484_CR22","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1016\/j.ajhg.2008.04.015","volume":"82","author":"HJ Zhu","year":"2008","unstructured":"Zhu HJ, Patrick KS, Yuan HJ et al (2008) Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basis. Am J Hum Genet 82(6):1241\u20131248","journal-title":"Am J Hum Genet"},{"issue":"3","key":"3484_CR23","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1124\/dmd.119.089680","volume":"48","author":"L Her","year":"2020","unstructured":"Her L, Zhu HJ (2020) Carboxylesterase 1 and Precision Pharmacotherapy: Pharmacogenetics and Nongenetic Regulators. Drug Metab Dispos 48(3):230\u2013244","journal-title":"Drug Metab Dispos"},{"key":"3484_CR24","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.bcp.2016.09.003","volume":"119","author":"J Shi","year":"2016","unstructured":"Shi J, Wang X, Nguyen JH et al (2016) Dabigatran etexilate activation is affected by the CES1 genetic polymorphism G143E (rs71647871) and gender. Biochem Pharmacol 119:76\u201384","journal-title":"Biochem Pharmacol"},{"issue":"13","key":"3484_CR25","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1161\/CIRCULATIONAHA.112.001233","volume":"127","author":"G Pare","year":"2013","unstructured":"Pare G, Eriksson N, Lehr T et al (2013) Genetic determinants of dabigatran plasma levels and their relation to bleeding. Circulation 127(13):1404\u20131412","journal-title":"Circulation"},{"issue":"10","key":"3484_CR26","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1007\/s00228-016-2094-1","volume":"72","author":"Z Zhao","year":"2016","unstructured":"Zhao Z, Li X, Sun S et al (2016) Impact of genetic polymorphisms related to clopidogrel or acetylsalicylic acid pharmacology on clinical outcome in Chinese patients with symptomatic extracranial or intracranial stenosis. Eur J Clin Pharmacol 72(10):1195\u20131204","journal-title":"Eur J Clin Pharmacol"},{"issue":"18","key":"3484_CR27","first-page":"e895","volume":"145","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D et al (2022) 2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 145(18):e895\u2013e1032","journal-title":"Circulation"},{"issue":"36","key":"3484_CR28","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M et al (2021) 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 42(36):3599\u20133726","journal-title":"Eur Heart J"},{"issue":"4","key":"3484_CR29","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1097\/FJC.0000000000000873","volume":"76","author":"J Hu","year":"2020","unstructured":"Hu J, Wu Y, Zhou X et al (2020) Beneficial Effects of Sacubitril\/Valsartan at Low Doses in an Asian Real-World Heart Failure Population. J Cardiovasc Pharmacol 76(4):445\u2013451","journal-title":"J Cardiovasc Pharmacol"},{"issue":"20","key":"3484_CR30","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","volume":"382","author":"PW Armstrong","year":"2020","unstructured":"Armstrong PW, Pieske B, Anstrom KJ et al (2020) Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med 382(20):1883\u20131893","journal-title":"N Engl J Med"},{"issue":"5","key":"3484_CR31","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1002\/ejhf.1342","volume":"21","author":"H Nougu\u00e9","year":"2019","unstructured":"Nougu\u00e9 H, Pezel T, Picard F et al (2019) Effects of sacubitril\/valsartan on neprilysin targets and the metabolism of natriuretic peptides in chronic heart failure: a mechanistic clinical study. Eur J Heart Fail 21(5):598\u2013605","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"3484_CR32","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1080\/00498254.2017.1295171","volume":"48","author":"I Hanna","year":"2018","unstructured":"Hanna I, Alexander N, Crouthamel MH et al (2018) Transport properties of valsartan, sacubitril and its active metabolite (LBQ657) as determinants of disposition. Xenobiotica 48(3):300\u2013313","journal-title":"Xenobiotica"},{"key":"3484_CR33","doi-asserted-by":"crossref","unstructured":"Yerrakula G, Abraham S, John S et al (2022) Major implications of single nucleotide polymorphisms in human carboxylesterase 1 on substrate bioavailability. Biotechnol Genet Eng Rev 1\u201319","DOI":"10.1080\/02648725.2022.2108997"},{"issue":"3","key":"3484_CR34","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1111\/bcpt.12916","volume":"122","author":"M Neuvonen","year":"2018","unstructured":"Neuvonen M, Tarkiainen EK, Tornio A et al (2018) Effects of Genetic Variants on Carboxylesterase 1 Gene Expression, and Clopidogrel Pharmacokinetics and Antiplatelet Effects. Basic Clin Pharmacol Toxicol 122(3):341\u2013345","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"12","key":"3484_CR35","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/j.dld.2013.05.010","volume":"45","author":"F Tavano","year":"2013","unstructured":"Tavano F, Palmieri O, di Mola FF et al (2013) Genetic variants of membrane metallopeptidase genes in inflammatory bowel diseases. Dig Liver Dis 45(12):1003\u20131010","journal-title":"Dig Liver Dis"},{"issue":"20","key":"3484_CR36","doi-asserted-by":"publisher","first-page":"5247","DOI":"10.1016\/j.cell.2021.08.025","volume":"184","author":"D Griesemer","year":"2021","unstructured":"Griesemer D, Xue JR, Reilly SK et al (2021) Genome-wide functional screen of 3\u2019UTR variants uncovers causal variants for human disease and evolution. Cell 184(20):5247-5260.e19","journal-title":"Cell"},{"key":"3484_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.thromres.2016.05.025","volume":"144","author":"C Dimatteo","year":"2016","unstructured":"Dimatteo C, D\u2019Andrea G, Vecchione G et al (2016) Pharmacogenetics of dabigatran etexilate interindividual variability. Thromb Res 144:1\u20135","journal-title":"Thromb Res"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-023-03484-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-023-03484-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-023-03484-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T08:07:37Z","timestamp":1681718857000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-023-03484-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,28]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["3484"],"URL":"https:\/\/doi.org\/10.1007\/s00228-023-03484-6","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"type":"print","value":"0031-6970"},{"type":"electronic","value":"1432-1041"}],"subject":[],"published":{"date-parts":[[2023,3,28]]},"assertion":[{"value":"8 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study involving human participants was approved by the Ethics Committee of Changsha Central Hospital affiliated to the University of South China. All patients in this study signed informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have approved the final manuscript and agreed to its publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}